3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Promyelocytic, Acute
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Tretinoin
10
Arsenic Trioxide
10
Methotrexate
7
Busulfan
7
Gemtuzumab
6
Cytarabine
6
Cyclophosphamide
6
Peripheral Blood Stem Cell Transplantation
5
Filgrastim
5
fludarabine phosphate
4
Idarubicin
4
Tacrolimus
3
Etoposide
3
Daunorubicin
3
Antilymphocyte Serum
3
lintuzumab
2
Topotecan
2
Radiotherapy
2
Mycophenolic Acid
2
Mercaptopurine
2
Cyclosporins
2
Cyclosporine
2
Bortezomib
2
Azacitidine
2
thymoglobulin
1
tamibarotene
1
sargramostim
1
romidepsin
1
merphos
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Leukemia, Promyelocytic, Acute
×
tamibarotene
×
Clear all
NCT00520208
2013-02-13
STAR-1
CytRx
Phase 2
Completed
15 enrolled